Connecticut Senate Bill SB00033

Connecticut 2019 Regular Session

• Introduced: 1/15/19
• Refer: 1/15/19
• Refer: 3/8/19
• Report Pass: 3/14/19
• Refer: 3/27/19
• Report Pass: 4/2/19
• Refer: 5/8/19
• Report Pass: 5/13/19
• Report Pass: 5/15/19

Caption

An Act Concerning Health Insurance Coverage Of Orally And Intravenously Administered Prescription Drugs.

Impact

The implementation of SB00033 would affect health insurance policies across the state, potentially leading to increased access to medications that are administered orally. By mandating equal coverage for these types of drugs, the bill aims to alleviate any unnecessary burdens that patients might encounter when prescribed medication in different forms. This equality in coverage could ensure that patients opt for the most appropriate medication without financial penalties based on the administration method.

Summary

SB00033 is an act concerning health insurance coverage of orally and intravenously administered prescription drugs. The bill stipulates that every individual and group health insurance policy issued or renewed on or after January 1, 2020, must provide coverage for orally administered prescription drugs on a basis that is no less favorable than that for intravenous drugs. This legislation is intended to ensure equitable treatment of both forms of medication, recognizing that many important treatments are available only in oral form.

Sentiment

The sentiment surrounding the bill appears to be supportive, particularly from patients, healthcare providers, and advocates who emphasize the importance of accessible healthcare. Supporters argue that equal coverage fosters better health outcomes by ensuring that patients have access to necessary treatments regardless of how they are administered. However, there may be concerns raised by insurance companies regarding the potential increase in costs associated with mandated coverage.

Contention

Notable points of contention could center on the extent to which insurance companies might argue against the financial implications of such mandates. There is a concern that requiring equal coverage could lead to higher premiums or reduced availability of certain medications if insurance providers face increased costs. Balancing the needs of patients with the fiscal realities of insurance operations may lead to ongoing debates about the long-term implications of SB00033 as it moves through the legislative process.